Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL783382 | 0.86 | USP2 (0.56) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL5873343 | 0.85 | — | — | |
| SCHEMBL29840591 | 0.83 | USP2 (0.53) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL5070659 | 0.78 | — | — | |
| SCHEMBL862245 | 0.76 | KDM4E (0.32) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL10656088 | 0.75 | — | — | |
| SCHEMBL17036956 | 0.73 | USP2 (0.43) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL12339103 | 0.73 | USP2 (0.43) | USP2TSHRALDH1A1KDM4ELMNA | |
| Ethane Dimethane Sulfonate SCHEMBL1336145 | 0.72 | USP2 (0.75) | USP2TSHRALDH1A1KDM4ELMNA | |
| SCHEMBL6020062 | 0.71 | USP2 (0.42) | USP2TSHRALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2054387-B1 | PROCESS FOR THE MANUFACTURE OF HI-6 DIMETHANESULFONATE | PHOENIX CHEMICALS LTD (GB) | 2012-11-21 | — | — | EP | claimed |
| US-8143406-B2 | Process for the manufacture of HI-6 dimethanesulfonate | PHOENIX CHEMICALS LIMITED (GB) | 2012-03-27 | — | — | US | claimed |
| US-20100016604-A1 | PROCESS FOR THE MANUFACTURE OF HI-6 DIMETHANESULFONATE | PHOENIX CHEMICALS LIMITED (GB) | 2010-01-21 | — | — | US | claimed |
| EP-2054387-A1 | PROCESS FOR THE MANUFACTURE OF HI-6 DIMETHANESULFONATE | Phoenix Chemicals Limited (GB) | 2009-05-06 | — | — | EP | claimed |
| WO-2008023205-A1 | PROCESS FOR THE MANUFACTURE OF HI-6 DIMETHANESULFONATE | PHOENIX CHEMICALS LIMITED (GB) | 2008-02-28 | — | — | WO | claimed |
| WO-1992017450-A1 | BIS-METHYLENE ETHER PYRIDINIUM COMPOUND PREPARATION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1992-10-15 | — | — | WO | claimed |
| US-5130438-A | Reaction of bis(methylsulfonoxymethyl)ether with pyridino-2-aldoxime and then isonicotinamide followed by ino exchanging chloride | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1992-07-14 | — | — | US | claimed |
| US-4100200-A | Use of novel ethers as oxydimethylating agents | EASTMAN KODAK COMPANY (US) | 1978-07-11 | — | — | US | claimed |
| US-20250304529-A1 | BIOBASED CYANOACRYLATE COMPOUND | BOSTIK SA (FR) | 2025-10-02 | — | — | US | disclosed |
| EP-4286369-A1 | BIOBASED CYANOACRYLATE COMPOUND | Bostik SA (FR) | 2023-12-06 | — | — | EP | disclosed |
| EP-3126321-B1 | PROCESS FOR PREPARING 1,1-DISUBSTITUTED ETHYLENE MONOMERS | AFINITICA TECH S L (ES) | 2018-03-07 | — | — | EP | disclosed |
| EP-3126321-B1 | PROCESS FOR PREPARING 1,1-DISUBSTITUTED ETHYLENE MONOMERS | AFINITICA TECH S L (ES) | 2018-03-07 | — | — | EP | disclosed |
| US-9670145-B2 | Process for preparing 1,1-disubstituted ethylene monomers | AFINITICA TECHNOLOGIES, S. L. (ES) | 2017-06-06 | — | — | US | disclosed |
| US-9670145-B2 | Process for preparing 1,1-disubstituted ethylene monomers | AFINITICA TECHNOLOGIES, S. L. (ES) | 2017-06-06 | — | — | US | disclosed |
| WO-1992017450-A1 | BIS-METHYLENE ETHER PYRIDINIUM COMPOUND PREPARATION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1992-10-15 | — | — | WO | disclosed |
| WO-1992017450-A1 | BIS-METHYLENE ETHER PYRIDINIUM COMPOUND PREPARATION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1992-10-15 | — | — | WO | disclosed |
| US-5130438-A | Reaction of bis(methylsulfonoxymethyl)ether with pyridino-2-aldoxime and then isonicotinamide followed by ino exchanging chloride | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1992-07-14 | — | — | US | disclosed |
| US-5130438-A | Reaction of bis(methylsulfonoxymethyl)ether with pyridino-2-aldoxime and then isonicotinamide followed by ino exchanging chloride | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1992-07-14 | — | — | US | disclosed |
| US-4100200-A | Use of novel ethers as oxydimethylating agents | EASTMAN KODAK COMPANY (US) | 1978-07-11 | — | — | US | disclosed |
| US-4025542-A | Novel ethers, their preparation and use as oxydimethylating agents | EASTMAN KODAK COMPANY (US) | 1977-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304529-A1 | BIOBASED CYANOACRYLATE COMPOUND | BAP1, CBR1, CBR3 | USP2 1133/4885TSHR 4765/4885ALDH1A1 95/4885 |
| US-20100016604-A1 | PROCESS FOR THE MANUFACTURE OF HI-6 DIMETHANESULFONATE | DHX36, HAAO, INTS6 | USP2 1675/4885TSHR 4263/4885ALDH1A1 727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.